Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpitatug satetraxetan + pasritamig
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Alpitatug satetraxetan + pasritamig is an investigational combination of two human kallikrein-2 (KLK2)-targeted agents developed by Johnson & Johnson (Janssen) for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). Alpitatug satetraxetan (JNJ-69086420) is a first-in-class radioimmunoconjugate consisting of a humanized IgG1-kappa monoclonal antibody targeting KLK2, conjugated to the DOTA-derivative chelator satetraxetan and radiolabeled with the alpha-emitting radionuclide actinium-225. Pasritamig (JNJ-78278343) is a first-in-class bispecific IgG1 antibody and T-cell engager that simultaneously binds KLK2 on prostate cancer cells and CD3 on T cells, redirecting T-cell-mediated cytotoxicity to the tumor. This combination is being evaluated in Phase 1 clinical trials to assess safety, tolerability, and preliminary efficacy in patients with mCRPC.
- Other names
- actinium (225Ac) alpitatug satetraxetan + pasritamigactinium Ac 225 alpitatug satetraxetan + pasritamigJNJ-6420 + JNJ-78278343JNJ-69086420 + JNJ-78278343
02
Targets
HK2 (Hexokinase Type II)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on alpitatug satetraxetan + pasritamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpitatug satetraxetan + pasritamig.